Man

nigel peter murray

Profesor

Universidad Finis Terrae

Santiago, Chile

Líneas de Investigación


La detección y caracterización of CTCs y metástasis en cáncer de próstata y del colon, el efecto de la enfermedad mínimo residual en el pronostico y la influencia del sistema inmunología en la respuesta de pacientes con cáncer no-metastásica.

Educación

  •  Hematología, CONACEM. Chile, 1995
  •  Cell and Immunobiology BSc (Hons), university of wales. Reino Unido, 1982
  •  MB BCH, university of wales. Reino Unido, 1987
  •  Medicina Interna, Royal College of Physicians UK. Chile, 1992
  •  medico cirujano, UNIVERSIDAD DE CHILE. Chile, 1994

Experiencia Académica

  •   REgistrar Full Time

    UNIVERSITY OF LIVERPOOL

    Medicine

    Liverpool, Reino Unido

    1990 - 1993

  •   Lecturer Full Time

    University of Manchester

    medicina

    Manchester, Reino Unido

    1993 - 1994

  •   Lecturer Part Time

    Universidad Mayor

    Medicina

    Santiago, Chile

    2008 - 2015

  •   Profesor Full Time

    Universidad Finis Terrae

    Medicina

    Santiago, Chile

    2015 - At present

Experiencia Profesional

  •   Director -Médico Part Time

    Instituto Bio-Oncologia

    Santiago, Chile

    1996 - 2015

Formación de Capital Humano


Ganador el Premio Perez-Castro por el mejor articulo de investigación publicado en los Archivos Españoles de Urología
2011.2012, 2017 y 2019, finalista 2014 y 2015

Ganador el Galardón Umberto Veronesi (Instituto Europeo de Oncología) 2016 Buenas Aires y 2017 Montevideo por el mejor trabajo científico

Ganador Premio SLAURO 2016 Santiago por el mejor trabajo cientifico

Ganador Premio SLAGO 2017 Santiago por el mejor trabajo científico en cáncer del colon

Ganador Premio Mejor presentación científico Congreso Internacional Congreso de Molecular Oncolgía, Grecia 2011


Premios y Distinciones

  •   Nigel P Murray

    UNIVERSIDAD FINIS TERRAE

    Chile, 2019

    1ª premio Prez Castro mejor articulo de investigación publicado en los Archivos Españoles de Urológica 2019. 2017, 2012 y 2011 POR LOS TRABAJOS EN CTCS, Y LA ENFERMEDAD MINIMA RESIDUAL

  •   Nigel P Murray

    UNIVERSIDAD FINIS TERRAE

    Chile, 2016

    PREMIO SLAURO POR EL MEJOR TRABAJO EN CTCS EN CÁNCER PROSTÁTICO

  •   Nigel P Murray

    UNIVERSIDAD FINIS TERRAE

    Chile, 2016

    GANADOR PREMIO POR EL MEJOR TRABAJO CIENTÍFICO EN CÁNCER DEL PRÓSTATA 2016 GALARDÓN UMBERTO VERONESI INSTITUTO EUROPEO DE ONCOLOGÍA, BUENOS AIRES


 

Article (43)

Minimal Residual Disease Defines the Risk and Time to Biochemical Failure in Patients with Pt2 and Pt3a Prostate Cancer Treated With Radical Prostatectomy: An Observational Prospective Study
The CAPRA score versus sub-types of minimal residual disease to predict biochemical failure after external beam radiotherapy
Biomarkers detecting minimal residual disease in solid tumors: what do they mean in the clinical management of patients?
Circulating prostate cells and bone marrow micrometastasis are determinant in risk and time to biochemical progression in localized prostate cancer [CÉlulas prostÁticas circulantes y micro-metÁstasis en mÉdula Ósea determinantes en el riesgo y en el tiempo de progresiÓn bioquÍmica en cÁncer prostÁtico localizado]
Common B-cell acute lymphoblastic leukaemia in a 70-year-old woman presenting 2 years after carboplatin-taxane radiotherapy for endometrial cancer
Effect of FOLFOX on minimal residual disease in Stage III colon cancer and risk of relapse
Minimal residual disease and not the treatment predicts biochemical recurrence in patients with low-risk prostate cancer [La enfermedad mínima residual y no el tratamiento predice la recidiva bioquímica en sujetos con cáncer prostático de bajo riesgo]
Predictive value of neutrophil to lymphocyte ratio in the diagnosis of significant prostate cancer at initial biopsy: A comparison with free percent prostate specific antigen, prostate specific antigen density and primary circulating prostate cells
Primary circulating prostate cells, age, and prostate volume predict prostate cancer in subjects with indication of a second prostate biopsy [Las células prostáticas circulantes primarias, edad y volumen prostático predicen el cáncer prostático en sujetos con indicación de una segunda biopsia prostática]
Short-term dose-escalated romiplostim for preparing an adult patient with persistent newly diagnosed primary immune thrombocytopenia for splenectomy
Subtypes of minimal residual disease, association with Gleason score, risk and time to biochemical failure in pT2 prostate cancer treated with radical prostatectomy
10 year biochemical failure free survival of men with CD82 positive primary circulating prostate cells treated by radical prostatectomy
Combining the Prostate Cancer Risk Index (PRIX) with the presence of secondary circulating prostate cells to predict the risk of biochemical failure after radical prostatectomy for prostate cancer
Minimum residual disease in patients post radical prostatectomy for prostate cancer: Theoretical considerations, clinical implications and treatment outcome
Comparison of two on-line risk calculators versus the detection of circulating prostate cells for the detection of high risk prostate cancer at first biopsy
Comparison between use of PSA kinetics and bone marrow micrometastasis to define local or systemic relapse in men with biochemical failure after radical prostatectomy for prostate cancer
Limited improvement of incorporating primary circulating prostate cells with the CAPRA score to predict biochemical failure-free outcome of radical prostatectomy for prostate cancer
Prediction model for early biochemical recurrence after radical prostatectomy based on the Cancer of the Prostate Risk Assessment score and the presence of secondary circulating prostate cells
Comparison of the formula of PSA, age, prostate volume and race versus PSA density and the detection of primary malignant circulating prostate cells in predicting a positive initial prostate biopsy in chilean men with suspicion of prostate cancer
Comparison of the Walz nomogram and presence of secondary circulating prostate cells for predicting early biochemical failure after radical prostatectomy for prostate cancer in chilean men
Diagnostic yield of primary circulating tumor cells in women suspected of breast cancer: The BEST (breast early screening test) study
Expression of P504S and matrix metalloproteinase-2 in circulating prostate cells disseminated as a result of transrectal ultrasound guided biopsy as determined by immunocytochemistry: Clinical implications
Head-to-head comparison of the Montreal nomogram with the detection of primary malignant circulating prostate cells to predict prostate cancer at initial biopsy in Chilean men with suspicion of prostate cancer
Head-to-head comparison of the Montreal nomogram with the detection of primary malignant circulating prostate cells to predict prostate cancer at initial biopsy in Chilean men with suspicion of prostate cancer.
Possible role of HER-2 in the progression of prostate cancer from primary tumor to androgen independence
Prostate cancer screening in the fit chilean elderly: A head to head comparison of total serum PSA versus age adjusted PSA versus primary circulating prostate cells to detect prostate cancer at initial biopsy
Secondary circulating tumor cells (CTCs) but not primary CTCs are associated with the clinico-pathological parameters in chilean patients with colo-rectal cancer
A comparative performance analysis of total PSA, percentage free PSA, PSA velocity, and PSA density versus the detection of primary circulating prostate cells in predicting initial prostate biopsy findings in Chilean men.
Elimination of primary circulating prostate cells after radical prostatectomy for prostate cancer decreases the risk of future biochemical failure
Primary circulating prostate cells are not detected in men with low grade small volume prostate cancer
Screening for prostate cancer: New markers and future aspects
A performance analysis of the presence of malignant circulating prostate cells as a predictive factor for the detection of prostate cancer in the first, second and third prostate biopsy
Circulating prostate cells found in men with benign prostate disease are P504S negative: Clinical implications
Cost-benefit of incorporating the detection of circulating prostate cells in a screening programme for prostate cancer
Effect of androgen blockade on HER-2 and matrix metalloproteinase-2 expression on bone marrow micrometastasis and stromal cells in men with prostate cancer.
Secondary circulating prostate cells predict biochemical failure in prostate cancer patients after radical prostatectomy and without evidence of disease.
Redefining micrometastasis in prostate cancer - a comparison of circulating prostate cells, bone marrow disseminated tumor cells and micrometastasis: Implications in determining local or systemic treatment for biochemical failure after radical prostatecto
Redefining micrometastasis in prostate cancer - a comparison of circulating prostate cells, bone marrow disseminated tumor cells and micrometastasis: Implications in determining local or systemic treatment for biochemical failure after radical prostatectomy
Diagnostic performance of malignant prostatic cells detection in blood for early detection of prostate cancer: Comparison to prostatic biopsy Rendimiento diagnóstico de la detección de células prostáticas malignas en la circulación sanguínea para la detección precoz de cáncer prostático: UNA comparación con la biopsia prostática
Positive HER-2 protein expression in circulating prostate cells and micro-metastasis, resistant to androgen blockage but not diethylstilbestrol
Positive HER-2 protein expression in circulating prostate cells and micro-metastasis, resistant to androgen blockage but not diethylstilbestrol.
Detection and characteristics of primary circulating prostate cells; association with micrometastasis and implications for surgical treatment of men with prostate c‡ncer [Detecci—n y caracter’sticas de cŽlulas prost‡ticas circulantes primarias, asociaci—n con la presencia de micromet‡stasis y las implicaciones para el tratamiento quirœrgico en hombres con c‡ncer prost‡tico]
P504S expressing circulating prostate cells as a marker for prostate cancer

CaseReport (2)

Manejo de una paciente embarazada con déficit congénito de Factor VII leve
ANTICUERPO ANTI-P1 Y EMBARAZO

Note (1)

Identification and Characterization of Circulating Tumor Cells in Men Who have Undergone Prostatectomy for Clinically Localized, High Risk Prostate Cancer

Review (2)

Minimal residual disease in prostate cancer patients after primary treatment: theoretical considerations, evidence and possible use in clinical management
The presence of secondary circulating prostate tumour cells determines the risk of biochemical relapse for patients with low- and intermediate-risk prostate cancer who are treated only with external radiotherapy
42
nigel murray

Profesor

Medicina

Universidad Finis Terrae

Santiago, Chile

20
Cynthia Fuentealba

Médico Urólogo

Urología

Hospital DIPRECA

Santiago, Chile

5
Pablo Tapia

Jefe Técnico Unidad de Paciente Crítico (UPC)

Unidad Paciente Critico (UPC)

Hospital Clinico Metropolitano La Florida

Santiago, Chile

1
Gloria Calaf

Directora Laboratorio Biología del cáncer

Universidad de Tarapacá

Arica, Chile